FDA Confirms GLP-1 RA Safety Review: No Increas...

By HEOR Staff Writer

February 2, 2026

GLP-1 RA Safety Review Clears Suicidal Risk Concerns In a pivotal GLP-1 RA safety review, the U.S. Food and Drug Administration (FDA) has concluded, following an extensive analysi...
Expansion of Generic Medicines Authorization in Portugal
CHMP January 2026 Approvals: Expanding Access to Innovative Therapies
Characterizing Burnout in Health Professionals: Insights from the BEATS Study...
Latin America Pharma Growth: Boehringer Ingelheim’s Strategic Investmen...
Accelerating FAST-EU Clinical Trials
Alzheimer’s Care Innovation: Advancing Implementation Across Europe
Long-Term Benefits of Composite Treatment Targets in Type 2 Diabetes Management
EU Medicine Authorizations 2025: A Milestone for Innovation and Accessibility
FDA Updates Labeling on Febrile Seizure Risks in Influenza Vaccine for Children
Obesity Medication Guidelines: Evidence-Based Approaches to Effective Treatment
Equity-Based Pricing: Enhancing Value in Primary Care through Socioeconomic C...
β-Blockers Myocardial Infarction: Reevaluating Their Role in Patients with Pr...